5V2Q

CaV beta2a subunit: CaV1.2 AID-CEN complex


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.7 Å
  • R-Value Free: 0.196 
  • R-Value Work: 0.154 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Stapled Voltage-Gated Calcium Channel (CaV) alpha-Interaction Domain (AID) Peptides Act As Selective Protein-Protein Interaction Inhibitors of CaV Function.

Findeisen, F.Campiglio, M.Jo, H.Abderemane-Ali, F.Rumpf, C.H.Pope, L.Rossen, N.D.Flucher, B.E.DeGrado, W.F.Minor, D.L.

(2017) ACS Chem Neurosci 8: 1313-1326

  • DOI: 10.1021/acschemneuro.6b00454
  • Primary Citation of Related Structures:  5V2P

  • PubMed Abstract: 
  • For many voltage-gated ion channels (VGICs), creation of a properly functioning ion channel requires the formation of specific protein-protein interactions between the transmembrane pore-forming subunits and cystoplasmic accessory subunits. Despite t ...

    For many voltage-gated ion channels (VGICs), creation of a properly functioning ion channel requires the formation of specific protein-protein interactions between the transmembrane pore-forming subunits and cystoplasmic accessory subunits. Despite the importance of such protein-protein interactions in VGIC function and assembly, their potential as sites for VGIC modulator development has been largely overlooked. Here, we develop meta-xylyl (m-xylyl) stapled peptides that target a prototypic VGIC high affinity protein-protein interaction, the interaction between the voltage-gated calcium channel (CaV) pore-forming subunit α-interaction domain (AID) and cytoplasmic β-subunit (CaVβ). We show using circular dichroism spectroscopy, X-ray crystallography, and isothermal titration calorimetry that the m-xylyl staples enhance AID helix formation are structurally compatible with native-like AID:CaVβ interactions and reduce the entropic penalty associated with AID binding to CaVβ. Importantly, electrophysiological studies reveal that stapled AID peptides act as effective inhibitors of the CaVα1:CaVβ interaction that modulate CaV function in an CaVβ isoform-selective manner. Together, our studies provide a proof-of-concept demonstration of the use of protein-protein interaction inhibitors to control VGIC function and point to strategies for improved AID-based CaV modulator design.


    Organizational Affiliation

    Molecular Biophysics & Integrated Imaging Division, Lawrence Berkeley National Laboratory , Berkeley, California 94720, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Voltage-dependent L-type calcium channel subunit beta-2,Voltage-dependent L-type calcium channel subunit beta-2
A
346Rattus norvegicusGene Names: Cacnb2 (Cacnlb2)
Find proteins for Q8VGC3 (Rattus norvegicus)
Go to UniProtKB:  Q8VGC3
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Voltage-dependent L-type calcium channel subunit alpha-1C
B
19Homo sapiensGene Names: CACNA1C (CACH2, CACN2, CACNL1A1, CCHL1A1)
Find proteins for Q13936 (Homo sapiens)
Go to Gene View: CACNA1C
Go to UniProtKB:  Q13936
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
8VY
Query on 8VY

Download SDF File 
Download CCD File 
B
1,3-bis(bromomethyl)benzene
alpha,alpha'-dibromo-m-xylene
C8 H8 Br2
OXHOPZLBSSTTBU-UHFFFAOYSA-N
 Ligand Interaction
CL
Query on CL

Download SDF File 
Download CCD File 
A
CHLORIDE ION
Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-M
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.7 Å
  • R-Value Free: 0.196 
  • R-Value Work: 0.154 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 54.975α = 90.00
b = 61.920β = 90.00
c = 129.877γ = 90.00
Software Package:
Software NamePurpose
iMOSFLMdata reduction
SCALAdata scaling
REFMACrefinement
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationCountryGrant Number
National Institutes of Health/National Heart, Lung, and Blood InstituteUnited StatesR01-HL080050
National Institutes of Health/National Institute of General Medical SciencesUnited StatesR01-GM54616

Revision History 

  • Version 1.0: 2017-07-19
    Type: Initial release
  • Version 1.1: 2017-08-23
    Type: Data collection
  • Version 1.2: 2017-09-13
    Type: Author supporting evidence